
Sell, $15.85 target: the $54.97 price needs 14.6% growth forever
We initiate at Sell with a $15.85 target, a price return of −71.2%. Rocket Lab sells Electron launches and satellites and is building Neutron. The market pays 44.0x sales; our probability-weighted value is $13.83 a share, and the $28.73 bull target is 47.7% below the price.
- Neutron is a 2027 event. First flight is no earlier than 2027 after four date resets; we model 18 launches a year, and even 50 a year values the stock at $16.63.
- Space Systems is priced for +37.3pp extra growth a year. We model +30% in FY27E on a $1.71bn backlog: $11.11 standalone.
- Cash and investments of $4.70bn are $6.71 a share. Weighted diluted shares rise from 530.7m in FY25A to 700.9m in FY27E; Iridium adds $1.69.
What the market is missing. Near-term numbers agree: FY27E revenue is 0.4% below consensus. The price needs 14.6% terminal growth, or a 4.5% cost of equity, below the 4.9% risk-free rate.
Catalysts. Q4 results (Feb 2027), Neutron tank qualification (Q1 2027), first flight (2027), Iridium close (mid-2027).
Valuation and target. DCF plus Iridium at 12.5x gives a $12.80 base; bear $8.05 (30%) and bull $25.06 (20%) weight to $13.83, rolled to $15.85. EV/sales gives $16.88.
Risks. Against our Sell: Neutron at 50 a year (+$3.83), Iridium at 16.2x (+$2.50). None nears the price.
| Year to 31 Dec, US$ | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue ($m) | 436 | 602 | 982 | 1,325 | 1,734 |
| Growth y/y | – | 38.0% | 63.2% | 34.8% | 30.9% |
| EBITDA ($m) | −156 | −185 | −180 | −68 | 132 |
| Margin | −35.8% | −30.7% | −18.3% | −5.1% | 7.6% |
| Net income ($m) | −190 | −198 | −196 | −41 | 81 |
| EPS ($) | −0.38 | −0.37 | −0.31 | −0.06 | 0.12 |
| Growth y/y | n.m. | n.m. | n.m. | n.m. | n.m. |
| Free cash flow ($m) | −116 | −322 | −241 | 7 | 248 |
| At $54.97 | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| P/E | n.m. | n.m. | n.m. | n.m. | 478x |
| EV/EBITDA | n.m. | n.m. | n.m. | n.m. | 256x |
| P/B | 100.7x | 22.4x | 6.6x | 6.6x | 6.4x |
| FCF yield | −0.3% | −0.8% | −0.6% | 0.0% | 0.6% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| ROE | −49.7% | −11.5% | −3.4% | −0.7% | 1.3% |
| Net debt / EBITDA | Net cash | Net cash | Net cash | Net cash | Net cash |
| P/E at our $15.85 target | n.m. | n.m. | n.m. | n.m. | 138x |
Source: Company filings (A); Penmark Research model (E); Yahoo Finance. Right: multiples at the $54.97 model price on diluted shares; only the last row is at target. n.m. = negative. Shaded = estimates.
Base value is $12.80; even the 12-month bull target of $28.73 is 47.7% below the $54.97 price
Source: Yahoo Finance; Penmark Research model. Case values rolled 12 months at the 14.65% cost of equity
Neutron $70m, 55% margin, 50 a year; Space Systems +45% fading to 6%; Iridium 16.2x. Target $28.73 (−47.7%).
Neutron flies 2027, $60m, 45% margin, 18 a year; Space Systems +30% fading to 4%; Iridium 12.5x. Target $14.67 (−73.3%).
Neutron slips to 2028, $50m, 30% margin, 8 a year; Space Systems +18%; Iridium 10.0x. Target $9.23 (−83.2%).
| Income statement, US$m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 436 | 602 | 982 | 1,325 | 1,734 |
| Gross profit | 116 | 207 | 349 | 424 | 560 |
| EBITDA | −156 | −185 | −180 | −68 | 132 |
| EBIT | −190 | −229 | −260 | −167 | 11 |
| Net interest, other | 0 | 3 | 71 | 126 | 74 |
| Income tax | 1 | −28 | 7 | 0 | 4 |
| Net income, reported | −190 | −198 | −196 | −41 | 81 |
| Memo: SBC | 57 | 71 | 84 | 93 | 95 |
| Cash flow, US$m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Operating cash flow | −49 | −166 | −117 | 167 | 398 |
| o/w customer deposits | – | −21 | 197 | 71 | 143 |
| Capex | −67 | −156 | −124 | −160 | −150 |
| Free cash flow | −116 | −322 | −241 | 7 | 248 |
| FCF excl. deposits | – | −301 | −439 | −63 | 104 |
| Memo: acquisitions | 0 | −132 | −44 | – | – |
| Memo: Iridium cash | – | – | – | −2,737 | – |
| Year-end cash | 419 | 1,104 | 4,682 | 1,953 | 2,201 |
| Balance sheet, US$m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash, investments | 419 | 1,104 | 4,682 | 1,953 | 2,201 |
| PP&E and intangibles | 253 | 544 | 735 | 796 | 825 |
| Goodwill | 71 | 206 | 301 | 301 | 301 |
| Iridium, at cost | – | – | – | 2,737 | 2,737 |
| Customer deposits | 216 | 195 | 393 | 464 | 607 |
| Debt, finance leases | 416 | 169 | 17 | 17 | 17 |
| Net cash | 2 | 935 | 4,665 | 1,935 | 2,183 |
| Equity | 382 | 1,722 | 5,799 | 5,850 | 6,026 |
| Per share and KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Diluted shares (m) | 496 | 531 | 642 | 701 | 701 |
| EPS, reported ($) | −0.38 | −0.37 | −0.31 | −0.06 | 0.12 |
| Dividend per share ($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF/share ($) | −0.23 | −0.61 | −0.38 | 0.01 | 0.35 |
| Book value/share ($) | 0.77 | 3.24 | 9.03 | 8.35 | 8.60 |
| Electron+HASTE launches | 16 | 21 | 25 | 30 | 33 |
| Neutron launches | 0 | 0 | 0 | 1 | 3 |
| SS revenue ($m) | – | 403 | 743 | 966 | 1,207 |
Source: Company filings (A); Penmark Research model (E); company filings (FY24A balance sheet). Scenario % = today’s value vs the $54.97 price; 12-month targets in text. Statements standalone; Iridium at cost from mid-2027. SBC = stock-based compensation; SS = Space Systems. Shaded = estimates.
Margins turn positive in FY28E, and our FY27E EPS is 35% above a consensus set before the print
| Growth, margins (%) | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y | |||||
| Sales | 78.3% | 38.0% | 63.2% | 34.8% | 30.9% |
| EBITDA | n.m. | n.m. | n.m. | n.m. | n.m. |
| EBIT | n.m. | n.m. | n.m. | n.m. | n.m. |
| EPS | n.m. | n.m. | n.m. | n.m. | n.m. |
| DPS | – | – | – | – | – |
| Margins | |||||
| Gross margin | 26.6% | 34.4% | 35.5% | 32.0% | 32.3% |
| EBITDA margin | −35.8% | −30.7% | −18.3% | −5.1% | 7.6% |
| EBIT margin | −43.5% | −38.0% | −26.4% | −12.6% | 0.6% |
| FCF margin | −26.6% | −53.5% | −24.6% | 0.6% | 14.3% |
| EBITDA / net interest | n.m. | n.m. | n.m. | n.m. | 1.8x |
| Capex / sales | 15.4% | 26.0% | 12.6% | 12.1% | 8.6% |
| Ratios and valuation | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Returns and leverage | |||||
| ROE | −49.7% | −11.5% | −3.4% | −0.7% | 1.3% |
| ROA | −16.8% | −9.1% | −3.1% | −0.6% | 1.2% |
| ROCE | −23.8% | −12.1% | −4.5% | −2.8% | 0.2% |
| Net debt / equity | −1% | −54% | −80% | −33% | −36% |
| Net debt / EBITDA | n.m. | n.m. | n.m. | n.m. | n.m. |
| Valuation at $54.97 | |||||
| P/E | n.m. | n.m. | n.m. | n.m. | 478x |
| EV/EBITDA | n.m. | n.m. | n.m. | n.m. | 256x |
| FCF yield | −0.3% | −0.8% | −0.6% | 0.0% | 0.6% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| P/E at our $15.85 target | n.m. | n.m. | n.m. | n.m. | 138x |
Source: Company filings (A); Penmark Research model (E); company filings (FY24A balance sheet). ROE and ROA use year-end equity and total assets net of operating payables. Multiples at the $54.97 model price on 700.9m diluted shares, EV $33.8bn. n.m. = not meaningful (negative). No dividend is paid.
| Ours vs consensus | Q4 FY26E | FY26E | FY27E |
|---|---|---|---|
| Revenue ($m) | |||
| Penmark estimate | 280 | 982 | 1,325 |
| Consensus | 266 | 959 | 1,330 |
| Prior-year period | 180 | 602 | 982 |
| Diff. vs consensus | +5.1% | +2.4% | −0.4% |
| Growth y/y (Penmark) | +55.9% | +63.2% | +34.8% |
| EPS ($) | |||
| Penmark estimate | −0.03 | −0.31 | −0.06 |
| Consensus | −0.05 | −0.27 | −0.09 |
| Prior-year period | – | −0.37 | −0.31 |
| Diff. vs consensus | +37% | −13.0% | +35.1% |
| Growth y/y (Penmark) | n.m. | n.m. | n.m. |
Source: Company filings; Penmark Research model (E). Consensus: S&P Global via StockAnalysis, Yahoo Finance, before the 9 Nov print; Q4 EPS from Yahoo Finance. Yahoo’s later mean is $1,352m revenue and −$0.09 EPS for FY27E.
Source: Company filings (A); Penmark Research model (E); consensus: S&P Global via StockAnalysis, Yahoo Finance, pre-print
Four dated events test the thesis; RKLB trades at 11x the peer sales multiple
| Metric | RKLB | Peer median | Difference |
|---|---|---|---|
| Valuation | |||
| EV / TTM sales | 44.0x | 3.9x | +1,020% |
| EV/sales per point of growth | 0.84x | 0.15x | +458% |
| Market value ($bn) | 38.5 | 2.0 | +1,870% |
| Growth and returns | |||
| Revenue growth, TTM | 52.5% | 44.1% | +8.4pp |
| Revenue, TTM ($m) | 769 | 426 | +80% |
| Operating margin, TTM | −29.1% | −27.5% | −1.6pp |
Source: Penmark Research model, 9 Nov 2026. Median of 5 peers (RDW, LUNR, PL, KTOS, VOYG); TTM to Jun 2026; % for multiples, pp for ratios.
- Feb 2027Q4 FY26 results: guide $270-290m; we sit at $280m, 5.1% above consensus $266m. FY27 launch growth above 20% tested.
- Q1 2027Neutron Stage 1 tank qualification. A further slip is our bear 1: −$0.27 a share.
- 2027Neutron first flight. We model one revenue flight in FY27E; success lifts the ramp, worth +$0.30 for +2 flights a year.
- Mid-2027Iridium close, about 44m RKLB shares issued. Base assumes 90% probability and 12.5x OEBITDA.
Source: Q3 FY26 call; Penmark Research model.
- Neutron slips again. Ramp moves a year right. Likelihood 40%; −$0.27/share.
- Iridium re-rates down. 10.0x OEBITDA after EMSS renewal. Likelihood 30%; −$1.66/share.
- Iridium at the 16.2x deal multiple (against our Sell). Likelihood 25%; +$2.50/share.
- Neutron at 50 launches a year (against our Sell). Market-implied path; +$3.83/share.
Source: Penmark Research model, 10 Nov 2026.
Source: Yahoo Finance prices; company-reported revenue and diluted shares; Penmark calculation, May 2024 to 10 Nov 2026
Source: Penmark Research model, prices 9 Nov 2026; company filings
RKLB trades with the space sector, not its own numbers: the sector ETF explains 66% of weekly moves
Source: Yahoo Finance weekly closes, 7 Nov 2025 to 10 Nov 2026; regression on 106 weekly returns, 1 Nov 2024 to 6 Nov 2026
Source: Company releases (backlog); Yahoo Finance quarter-end closes, 1Q25 to 3Q26 (3Q26 close $69.68 on 30 Sep 2026)
Source: Company 10-Q segment notes and Q3 FY26 call ($m)
Source: Penmark Research model (E); consensus: Yahoo Finance and S&P Global via StockAnalysis, pre-print
Source: Penmark Research model, 10 Nov 2026
Source: Penmark Research model, 10 Nov 2026
Over 12 months sales growth added $30.49 a share, but dilution and a lower multiple took $27.15
Source: Yahoo Finance; TTM revenue ($554.5m to $881.9m) and weighted diluted shares (Q3 FY25 528.7m to Q3 FY26 652.3m); Penmark calculation
Source: MarketBeat, S&P Global via StockAnalysis, 6-10 Nov 2026; Penmark Research model
| Bull claim | Evidence | Our answer |
|---|---|---|
| Demand is proven | Backlog $3.57bn, +52% on the prior quarter; 16 Neutron missions booked, several at $70m | Agreed; priced at 25.5x FY27E sales. Demand is not the debate, timing and value are. |
| Management beats its guide | Revenue above or inside the guide in 8 of 8 quarters; Q3 GAAP gross margin 33.6% vs 29-31% guide | Agreed; a $10m (4%) quarterly beat does not close a $42 gap. |
| Raising equity at $65 helps holders | Q3 ATM raised about $2.4bn, far above model value; it lifted value per share by $1.58 | Agreed, and in our number; weighted diluted shares rise 41% from FY24A to FY27E. |
| The Street is Buy | 18 of 22 Buy, none Sell, mean target $100.25, low $58 | Street targets sit above the price in every case; none models the 14.6% terminal growth the price needs. |
| The stock closed at $62.71 | The 10 Nov close was 14% above our intraday $54.97 | At $62.71 the return to target is −74.7%; the rating does not change. |
Source: Q3 FY26 release and call, 9 Nov 2026; MarketBeat; Yahoo Finance; Penmark Research model
Source: Penmark Research model, 10 Nov 2026
Four debates are worth $14.07 a share at the market view; $28.10 of the $42.17 gap is left unexplained
Each debate is priced alone: the market view replaces ours and every other input stays at base. Together they lift $12.80 to $26.87, still half the price. The stock needs more than winning any one debate.
| Debate | Market view | Penmark view | Evidence | What changes our view | Resolves | Value gap |
|---|---|---|---|---|---|---|
| 1 Discount rate | Sector beta 0.95 (cost of equity 8.9%) | Beta 2.31, cost of equity 14.7% | Beta regression; peer betas 1.9-3.3 | Neutron flies and RKLB beta falls toward 1.5 | First Neutron flight, 2027 | $5.95 |
| 2 Neutron cadence | 50 flights a year by FY34E | 18 a year; 1-3-5 ramp | Four date resets; no flight date; 16 missions booked | Flight 1 in H1 2027 and a ramp ahead of 1-3-5 | First flight, FY28 manifest, 2027 | $3.83 |
| 3 Space Systems growth | Bull path: +45% FY27E fading to 6% | +30% FY27E fading to 4% by FY40E | Backlog $1.71bn; CFO 20% long-run bar | Q4 print and SDA, Golden Dome awards add backlog | Q4 FY26 results, Feb 2027 | $1.78 |
| 4 Iridium value | 16.2x deal multiple on CY27E OEBITDA | 12.5x undisturbed, Aireon-consistent | Deal EV $8.0bn on FY25 OEBITDA of $495m; EMSS renewal 2027 | Close with PNT and direct-to-device growth | Close, mid-2027 | $2.50 |
Source: Penmark Research model, 10 Nov 2026; Q3 FY26 call
Source: Penmark Research model: each debate priced at the market view, others at base, 10 Nov 2026
| Date | Event | Debate | What it tests |
|---|---|---|---|
| Feb 2027 | Q4 FY26 results | 3 | Space Systems conversion, FY27 launch growth above 20% |
| Q1 2027 | Neutron Stage 1 tank qualification | 2 | Whether a 2027 first flight holds |
| 2027 | Neutron first flight | 1, 2 | Reuse, cadence and the right discount rate |
| Mid-2027 | Iridium close | 4 | Regulatory approvals; about 44m RKLB shares issued |
Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026
A rocket company that earns 80% of its revenue from satellites is valued at $38.5bn
Rocket Lab flies small rockets and builds spacecraft for governments. The twist is that the rocket it has not yet flown, Neutron, carries most of the value in the share price.
The scene
On 9 November 2026 Peter Beck, Rocket Lab’s founder, told investors there is still no first-flight date for Neutron, the rocket the company has promised for years. “We haven’t provided guidance on that just yet because we need to get through the Stage 1 tank,” he said. The same call reported revenue of $267.8m, above the top of guidance. Rocket Lab, founded in New Zealand in 2006 and now headquartered in Long Beach, California, flies small rockets and builds satellites, mostly for governments.
What it actually does
Launch Services sells rides on Electron, a small rocket with 75 successful missions through 2025, and on HASTE, a suborbital version. Space Systems builds satellites, solar panels and optics. Neutron, a reusable rocket for up to 13,000kg to low orbit, is not yet flying.
How the money comes in
Customers pay by contract, and often in advance: contract liabilities were $423.6m at 30 September 2026. In FY25, Space Systems brought in $402.8m (67% of revenue) and Launch Services $199.0m (33%). Launch is flights times price: 21 launches at about $9.5m each. Space Systems is projects; it was $214.8m in Q3, 80% of the quarter. Of each FY25 dollar, 34 cents was gross profit, spending took 72 cents and free cash flow was −53 cents.
Where the story turns
On 28 June Rocket Lab agreed to buy Iridium, the satellite-phone operator, at an enterprise value of $8.0bn. It sold about $2.4bn of new shares in Q3 to pay for it, lifting cash to $4.45bn ($4.70bn with investments). On 14 October it moved Neutron’s first flight into 2027; the shares fell 20.8% in three sessions.
Why it works, and why it might not
It works because demand is real: backlog is $3.57bn, up 52% on the prior quarter, with 117 launches booked and 16 Neutron missions, several at a $70m base price. It might not because the price already assumes a SpaceX-scale outcome: to justify $54.97 our model needs 14.6% growth in perpetuity. That is chapter 12.
Space Systems earns 67% of revenue and Launch 33%; every dollar of FY25A gross profit was spent twice over on research and overhead
Source: Company 10-K; Penmark Research model, FY25A ($m)
Source: Q3 FY26 release and call, 9 Nov 2026; company 10-Q
Source: Penmark Research model; highlighted boxes are the drivers we forecast
| Segment build, US$m | FY25A | FY26E | FY27E | FY28E | FY30E |
|---|---|---|---|---|---|
| Launch Services revenue | 199 | 239 | 359 | 527 | 950 |
| Electron and HASTE launches | 21 | 25 | 30 | 33 | 38 |
| Neutron launches | 0 | 0 | 1 | 3 | 8 |
| Space Systems revenue | 403 | 743 | 966 | 1,207 | 1,768 |
| Space Systems growth | – | 84.4% | 30.0% | 25.0% | 20.0% |
| Group gross margin | – | 35.5% | 32.0% | 32.3% | 36.9% |
Source: Penmark Research model; FY25A from company filings
Gross profit of $424m in FY27E still trails operating costs of $591m; Neutron closes the gap by FY30E
Source: Penmark Research model, FY27E ($m)
Source: Penmark Research model ($m)
Source: Penmark Research model ($m); EV on CY27E OEBITDA of $558.8m at 12.46x
Source: Company filings (A); Penmark Research model (E)
Launch is a $12.4bn market and Rocket Lab flew 5.5% of the world’s 329 orbital attempts in 2025
Demand is not the constraint; capacity and price are. Commercial launch revenue rose from $9.3bn in 2024 to $12.4bn in 2025, inside a $429bn space economy. SpaceX flew 165 of 329 attempts.
Source: Industry totals: Satellite Industry Association and launch-market sources, 2025; company filings
Source: Public launch logs compiled by Penmark Research, calendar 2025; Rocket Lab flew 21 including 3 suborbital HASTE
Source: US Space Force NSSL Phase 3 Lane 2 allocation, 54 missions, up to $13.68bn
| Rocket | Status, Nov 2026 | Reuse | Price evidence |
|---|---|---|---|
| Falcon 9 (SpaceX) | Operational; 165 flights in 2025 | Booster reused | $74m published price, Feb 2026 |
| Neutron (Rocket Lab) | No date; first flight no earlier than 2027 | Reusable first stage by design | $70m base; 16 missions booked |
| Vulcan (ULA) | Return to flight targeted 13 Nov 2026 | Expendable | About $214m per government mission |
| Ariane 6 (Arianespace) | Operational; 7 flights in 2025 | Expendable | EUR 82.07m for one Sentinel-1D mission |
| New Glenn (Blue Origin) | Has flown | Booster recovered | Not published |
Source: Company statements, launch-provider and US Space Force announcements, Nov 2026; Penmark Research compilation. Prices are published or reported figures, not quotes
Shareholders funded $3.9bn of equity in nine months; share count is up 3.0x since FY21
Source: Company cash flow statements ($m)
Source: Company income statements (m); Q3 FY26 ATM raised about $2.4bn gross
| Area | Finding | Why it matters |
|---|---|---|
| Control | Peter Beck is founder, CEO and Chair; 46.4m shares, 7.5% of votes. All directors and officers hold 8.4% | Founder alignment, but no separation of Chair and CEO; Merline Saintil is lead independent director |
| Board | 7 directors, 6 independent; three staggered classes; Series A Preferred (about 41m shares, votes 1:1) names a director | Staggered board slows any change of control |
| Pay | CEO FY25 pay $6.83m, of which $6.03m time-based stock; no bonus paid; executive awards carry no revenue, EBITDA, Neutron or TSR hurdle | Pay is not tied to per-share value or to the Neutron date |
| Related parties | One item above $120,000: Series A Preferred exchange with Beck’s trust; say-on-pay support about 80% in 2025 | Limited |
| Insiders | About $117m sold in four months to 2 Nov 2026 across 7 insiders; no open-market buys; 99.96% of dollars under 10b5-1 plans | Planned sales, but nobody is buying at $55 |
Source: FY2025 proxy statement (filed 6 Apr 2026) and Form 4 filings; insider data cover 8 Jul to 2 Nov 2026 only
Source: Company releases and call guidance; Penmark calculation
RKLB trades with the space-sector tape and the Neutron date, not with quarterly results
Four drivers explain the stock’s moves. The sector ETF explains 66% of weekly price variance and results days moved the stock 7.8% on average with almost no link to the revenue surprise (correlation 0.20). Neutron timing is the single topic management hedges most.
| Driver | What moves the stock | Evidence | Market reaction vs our model value | Debate | Next number |
|---|---|---|---|---|---|
| A Space-sector tape | Weekly moves track the space ETF (UFO); R² 66% against 21% for the S&P 500 | Factor regression, return decomposition | Not a company value; the ETF beta is 2.0 per 1.0 of sector move | 1 | UFO and RKLB weekly moves, ongoing |
| B Neutron first flight | Date slips cut 20.8% in three sessions, 13 to 16 Oct 2026 | Results-day moves, call Q&A (30 of 112 questions) | Close $64.22 to $50.84 (−$13.38); model: one-year delay −$0.27 | 2 | Stage 1 tank qualification, Q1 2027 |
| C Space Systems backlog | Backlog +52% on the prior quarter to $3.57bn; Q3 revenue beat the guide by 4.0% | Results-day moves (weak), call Q&A (17 of 112) | Market view adds $1.78 a share; Q3 print moved the stock −6.6% | 3 | Q4 FY26 results, Feb 2027 |
| D Funding and Iridium | $2.4bn ATM and 43.6m new shares; deal at 16.2x vs 12.5x undisturbed | Return decomposition, call Q&A (10 of 112) | Market view adds $2.50; dilution cost $15.55 over 12 months | 4 | Close, mid-2027 |
Source: Yahoo Finance, company transcripts and filings; Penmark Research calculations and model, Nov 2026. Regressions use 107 weekly returns, 1 Nov 2024 to 10 Nov 2026
Source: Yahoo Finance closes; Q3 FY26 is the 9 Nov close to the 10 Nov intraday model price; surprise vs guide midpoint
Source: Yahoo Finance; TTM revenue ($236.4m to $881.9m) and weighted diluted shares (Q3 FY23 484.0m to Q3 FY26 652.3m); Penmark calculation
Source: Penmark Research model, 10 Nov 2026 ($ per share)
The space ETF explains 66% of price variance; Neutron drew 30 of 112 analyst questions and management hedged on timing
Source: Yahoo Finance; OLS on 106 weekly log returns, 1 Nov 2024 to 6 Nov 2026; R-squared in %; Penmark calculation
Source: Company call transcripts, Q3 FY25 to Q3 FY26 (5 calls); Penmark classification
The ETF explains 66% of weekly variance with a coefficient of 2.0. Our model uses RKLB’s own beta of 2.31 (cost of equity 14.7%); valuing it at a sector beta of 0.95 would add $5.95 a share, to $18.75.
Next number: UFO ETF and RKLB weekly returns; a 1% sector move is about 2% for RKLB.
Three sessions of 13 to 16 Oct 2026 took the stock from $64.22 to $50.84 (−$13.38, −20.8%). Our model prices a one-year ramp delay at −$0.27, a gap of $13.11 a share. The price needs a faster ramp than the base case.
Next number: Stage 1 tank qualification, Q1 2027. Ours: first flight FY27E, one launch. Consensus: not published. Results days average ±7.8%.
The $1.71bn backlog is 1.47x the $1.17bn of Q4 FY26E plus FY27E Space Systems revenue we model. The market path (+45% fading to 6%) is worth $1.78 a share more than ours.
Next number: Q4 FY26 results, Feb 2027. Ours: revenue $280m. Consensus: $266.4m (+5.1% gap).
The deal is 16.2x FY25 OEBITDA against 12.5x undisturbed. Applying 16.2x to CY27E OEBITDA adds $2.50 a share. The $2.4bn Q3 ATM raised the share count to 639.2m common by 30 Sep 2026.
Next number: Regulatory approvals and close, mid-2027 (90% close probability in our value).
| Other factor | Result | Finding |
|---|---|---|
| 10-year Treasury yield | R² 2.4% alone; adds under 1pp to the UFO and S&P model | No explanatory power |
| S&P 500 | R² 21%; coefficient turns negative once UFO is included | Sector, not market, is the factor |
| ITA defense ETF | R² 21% | Weaker than the space ETF |
| Revenue surprise vs guide | Correlation 0.20 across eight results days | Results move the stock, but not through the headline beat |
| Short interest | 45.3m shares, 1.96 days to cover, little changed since July | Flat; no trend |
Source: Yahoo Finance weekly returns, 107 weekly returns from 1 Nov 2024 to 10 Nov 2026; FINRA short interest; Penmark calculation
Neutron’s date is still unknown, and even a ramp 2.8x our base case is worth only $16.63 a share
What the market believes
Consensus does not publish a Neutron path. At $54.97 the stock needs terminal growth of 14.6% ; even 50 launches a year is worth only $16.63 a share. The 14 Oct slip cost 20.8% in three sessions.
What it is worth
Our base case uses $60m a launch and 45% gross margin; the bull path (50 a year, $70m, 55%) adds $3.83 a share. Bull pricing alone adds $0.37; a one-year delay costs $0.27.
| Source | Evidence | Read-through |
|---|---|---|
| Company call, 9 Nov 2026 | No first-flight date; Stage 1 tank qualification ahead; 16 missions booked, eight signed in Q3, several at $70m | Demand is real; timing is the risk |
| Filings and updates | Date reset four times, from 2024 to H2 2025, 2026, Q4 2026, then no earlier than 2027 (8-K, 14 Oct 2026) | About three years of slip |
| Pentagon Office of Strategic Capital, 9 Nov 2026 | $150m conditional loan to raise Neutron’s flight rate after first launch; not closed | Support for the ramp, after a first flight |
| Call Q&A, five calls | 30 of 112 analyst questions on Neutron timing or price; management hedged on timing in 12 of 18 | Management is least sure on the date |
Source: Q3 FY26 call and 8-K; Q&A analysis of five calls, Penmark calculation
Source: Company results calls and 8-K, 27 Feb 2025 to 9 Nov 2026
Source: Penmark Research model
| Date | Signpost | Confirms | Breaks |
|---|---|---|---|
| Q1 2027 | Stage 1 tank qualified | Date given for 2027 | Second tank failure |
| 2027 | First flight and reuse | 1-3-5 cadence holds | Flight failure; ramp moves a year, −$0.27 |
| Contracts to 2027 | Price per launch | $70m base holds | Price falls toward $50m, −$0.37 |
Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026
Space Systems is 73% of FY27E revenue; a 4-point drift in long-run margin costs more than any growth surprise
What the market believes
FY27E consensus revenue is $1,330m against our $1,324.6m, a gap of −0.4%. The Q4 FY26 consensus of $266.4m sits 5.1% below our $280m. The market path in debate 3 is +45% in FY27E fading to 6%.
What it is worth
The market path adds $1.78 a share to our $12.80. A long-run margin of 32% instead of 36% costs $0.66; a 20% FY27E growth rate costs $0.13. The base case needs only 68% of the backlog (1.47x cover) to reach FY27E.
| Source | Evidence | Read-through |
|---|---|---|
| Q3 FY26 results | Space Systems revenue $214.8m, 80% of the quarter; backlog $3.57bn, +52% on the prior quarter; Space Systems share $1.71bn (48%) | Growth is funded by orders |
| CFO, Q3 call | Long-run growth bar about 20%; 32.9% of backlog converts within 12 months; Q4 lower on solar and platforms | Management itself sets the bar below the market’s 45% |
| Guidance record | Revenue above the range in 4 of 8 quarters, inside in 4, never below; Q3 GAAP gross margin 33.6% vs 29-31% guide, down from 38.2% in Q1 | Forecasts are conservative; margin is above guide but below Q1 |
Source: Q3 FY26 release and call, 9 Nov 2026; company filings; Penmark Research model
Source: Penmark Research model; management long-run bar about 20% (Q3 FY26 call)
Source: Q3 FY26 release and call; Penmark Research model ($m)
| Date | Signpost | Confirms | Breaks |
|---|---|---|---|
| Feb 2027 | Q4 FY26 results | Revenue at or above $280m; backlog above $3.6bn | Backlog falls; growth guided below 20% |
| FY27 budget cycle | Golden Dome, SDA Tranche 3 and 4 awards | Backlog adds (+5pp a year, $0.21) | Delayed awards (−$0.13) |
| Q4 FY26 to Q4 FY27 | Mynaric and platform margin | Segment margin toward 36% | Stalls near 32% (−$0.66) |
Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026
At $54.97 the market pays 4.0x our probability-weighted $13.83; even the 12-month bull target of $28.73 is 47.7% below it
What the market believes
Street targets run from $58 to $150 with a mean of $100.25. The price implies a beta of −0.08, a cost of equity of 4.5% against a 4.9% risk-free rate. Debates 1 to 4 explain $14.07 of the $42.17 gap.
What it is worth
Standalone DCF is $11.11; adding Iridium gives $12.80 in the base case. The probability-weighted value is $13.83 and the 12-month target $15.85, a −71.2% price return, Sell. The EV/sales cross-check gives $16.88, 31.9% above the DCF.
| Source | Evidence | Read-through |
|---|---|---|
| Model reverse DCF | Price needs 14.6% terminal growth, or a cost of equity of 4.5%, or +37.3pp of Space Systems growth every year to FY40E | No plausible single input closes the gap |
| Peers | RKLB 44.0x trailing sales vs 3.9x peer median; EV/sales per point of growth 0.84x vs 0.15x | Premium of 11x, on 52.5% growth vs 44.1% |
| Equity issuance | $2.4bn raised in Q3; period-end common shares 639.2m vs 543.6m at 31 Dec 2025; diluted standalone 700.9m | Weighted diluted shares rise 41% from FY24A to FY27E (495.9m to 700.9m) |
| Street | 18 of 22 Buy, none Sell; mean target $100.25, low $58 | Street values the optionality; we value the cash flows |
Source: Penmark Research model; MarketBeat and S&P Global, Nov 2026
Source: Penmark Research model, 10 Nov 2026; other inputs at base
| Date | Signpost | Confirms | Breaks |
|---|---|---|---|
| Mid-2027 | Iridium close | Valued at 16.2x on CY27E OEBITDA, +$2.50 | Approval slips; deal fails (10% probability) |
| 2027 | EMSS renewal at Iridium | Same rate holds | Lower rate; Iridium at 10.0x, −$1.66 |
| Each quarter | Weekly sector tape | Stock tracks UFO | Stock decouples from UFO and earnings |
Source: Penmark Research model; Iridium 8-K, 20 Oct 2026
Gross margin rose from −3.0% to 34.4% in four years, but every year burned cash and stock pay ran at 12% of FY25A revenue
Source: Company income statements; Penmark calculation
Source: Company releases and call guidance; Penmark calculation
| Five-year record | FY21A | FY22A | FY23A | FY24A | FY25A |
|---|---|---|---|---|---|
| Revenue ($m) | 62 | 211 | 245 | 436 | 602 |
| Growth | – | 239.0% | 15.9% | 78.3% | 38.0% |
| Gross margin | −3.0% | 9.0% | 21.0% | 26.6% | 34.4% |
| Operating margin | −164% | −64% | −73% | −44% | −38% |
| Stock-based compensation ($m) | 33 | 56 | 53 | 57 | 71 |
| SBC, % of revenue | 52.3% | 26.4% | 21.9% | 13.0% | 11.8% |
| Free cash flow ($m) | −97 | −149 | −154 | −116 | −322 |
| FCF, % of revenue | −157% | −71% | −63% | −27% | −53% |
Source: Company 10-K and 10-Q statements; Penmark Research calculation, FY21A to FY25A
| Q3 FY26 line | GAAP | Adjusted | What the gap is |
|---|---|---|---|
| EBITDA ($m) | −57.5 | −18.0 | $39.4m, mainly Iridium deal costs of $21.3m and stock compensation of $18.3m |
| Gross margin | 33.6% | 38.4% | Non-GAAP removes stock compensation and amortisation; guide was 35-37% non-GAAP |
| Free cash flow ($m) | −23.9 | n.a. | Operating cash flow $7.2m less capex $31.1m; deposits rose to $423.6m |
| Net interest and other ($m) | 3.0 | 28.6 interest | A $27.3m loss on extinguishing the 2029 convertible notes offsets $28.6m of interest income |
Source: Q3 FY26 release and call, 9 Nov 2026; Penmark Research model
Q4 FY26E revenue of $280m sits at the guide midpoint; FY27E of $1,324.6m is 0.4% below consensus
Every Q4 guided line sits inside its range, and our FY27E revenue is 0.4% below the Street. The forecast gap that matters is EPS: FY27E loss of $0.06 against consensus of $0.09, because we count interest on $4.7bn of cash.
| Driver path, US$m unless stated | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|
| Electron and HASTE launches | 25 | 30 | 33 | 36 | 38 |
| Revenue per launch ($m) | 9.6 | 10.0 | 10.4 | 10.8 | 11.2 |
| Neutron launches | 0 | 1 | 3 | 5 | 8 |
| Space Systems growth | 84.4% | 30.0% | 25.0% | 22.0% | 20.0% |
| Group revenue | 982 | 1,325 | 1,734 | 2,179 | 2,718 |
| Gross margin | 35.5% | 32.0% | 32.3% | 34.6% | 36.9% |
| EBITDA | −180 | −68 | 132 | 329 | 558 |
| Capex | −124 | −160 | −150 | −142 | −163 |
Source: Penmark Research model; FY26E includes 9M FY26 actuals
| Q4 FY26 guide | Range | Model | Position |
|---|---|---|---|
| Revenue ($m) | 270 to 290 | 280.0 | Midpoint |
| GAAP gross margin | 34% to 36% | 35.0% | Midpoint |
| GAAP operating expenses ($m) | 162 to 168 | 165.0 | Midpoint |
| Adjusted EBITDA ($m) | −20 to −14 | −17.0 | Midpoint |
| Net interest income ($m) | 45 | 45.0 | On guide |
| Stock-based compensation ($m) | 17 to 19 | 18.0 | Midpoint |
Source: Q3 FY26 release and call, 9 Nov 2026; Penmark Research model
| Line | Penmark | Consensus | Gap | Reason for the gap |
|---|---|---|---|---|
| Revenue Q4 FY26E ($m) | 280.0 | 266.4 | +5.1% | We use the guide midpoint; consensus sits below the guided range |
| Revenue FY26E ($m) | 982.3 | 959.2 | +2.4% | 9M actual $702.2m plus Q4 guide; consensus predates the print |
| Revenue FY27E ($m) | 1,324.6 | 1,330.0 | −0.4% | Space Systems growth of 30% is offset by a single Neutron flight |
| EPS FY26E ($) | −0.31 | −0.27 | −13.0% | Q3 deal costs of $21.3m and a $27.3m loss on retiring the 2029 notes |
| EPS FY27E ($) | −0.06 | −0.09 | +35.1% | Interest on $4.7bn cash against Neutron losses; consensus predates print |
Source: Consensus: S&P Global via StockAnalysis and Yahoo Finance, pre-print; Penmark Research model
A DCF gives $11.11 and an Iridium-inclusive base of $12.80; the EV/sales cross-check gives $16.88, 31.9% higher
We value Rocket Lab on a DCF to FY40E, plus Iridium at EV/OEBITDA weighted by a 90% close probability. Earnings are negative until FY28E, so P/E and EV/EBITDA are not usable. Listed peers are sub-scale and loss-making, so EV/sales against growth-adjusted peers is a cross-check, not the anchor. The 31.9% gap between the methods comes from the peer multiple: peers trade on sentiment, not on a reusable medium-lift ramp.
Source: Penmark Research model, valued 30 Sep 2026 ($m)
Source: Penmark Research model, 10 Nov 2026
Source: Penmark Research model, base case, $ per share
Source: Penmark Research model, $ per share
| Company | Price ($) | EV/TTM sales | TTM growth | Per point of growth |
|---|---|---|---|---|
| Redwire (RDW) | 8.11 | 3.00x | 63.1% | 0.048x |
| Intuitive Machines (LUNR) | 12.06 | 3.93x | 116.9% | 0.034x |
| Planet Labs (PL) | 14.41 | 12.60x | 44.1% | 0.286x |
| Kratos (KTOS) | 37.80 | 3.83x | 25.5% | 0.150x |
| Voyager (VOYG) | 27.91 | 9.81x | 10.6% | 0.923x |
| Peer median | 3.93x | 44.1% | 0.150x | |
| Rocket Lab (RKLB) | 54.97 | 44.00x | 52.5% | 0.838x |
Source: Prices, 9 Nov 2026; company 10-Q revenue, TTM to calendar Q2 2026; Penmark Research model
The 12-month target of $15.85 is a −71.2% price return from $54.97, well below the −10% Sell threshold
| Step | $ per share | Note |
|---|---|---|
| Standalone DCF value | 11.11 | Equity $7,667m at 30 Sep 2026, rolled to $7,786m at the 10 Nov price date; 700.9m diluted shares |
| Add Iridium, 90% close | 12.80 | Net value $1,882.4m; 43.6m new shares; $12.99 if the deal closes |
| Probability-weighted value | 13.83 | Bear $8.05 (30%), base $12.80 (50%), bull $25.06 (20%) |
| 12-month price target | 15.85 | Weighted value rolled 12 months at the 14.65% cost of equity |
| Price, 10 Nov 2026 intraday | 54.97 | Official close was $62.71 |
| Price return to target | −71.2% | (15.85 / 54.97) − 1; below −10%, so Sell |
Source: Penmark Research model, 10 Nov 2026
| Case | Probability | Value | 12-month target | 12-month return | Linked drivers |
|---|---|---|---|---|---|
| Bear | 30% | $8.05 | $9.23 | −83.2% | B Neutron slips to 2028, 8 a year, $50m; C Space Systems +18%; D Iridium 10.0x |
| Base | 50% | $12.80 | $14.67 | −73.3% | B one flight FY27E, 18 a year, $60m; C +30% fading to 4%; D 12.5x |
| Bull | 20% | $25.06 | $28.73 | −47.7% | B 50 a year, $70m, 55%; C +45% fading to 6%; D 16.2x |
Source: Penmark Research model. Probabilities are analyst judgements
Source: Penmark Research model, 10 Nov 2026
| Robustness test | Cost of equity | Value | 12-month total return | Rating |
|---|---|---|---|---|
| Base case at model cost of equity | 14.65% | $12.80 | −73.3% | Sell |
| Cost of equity −1 point | 13.65% | $13.35 | −72.4% | Sell |
| Cost of equity +1 point | 15.65% | $12.34 | −74.0% | Sell |
| Beta at high end (relevered peer median) | 16.28% | $12.09 | −74.4% | Sell |
| Sector beta 0.95 (the price-implied view) | 8.89% | $18.75 | −62.9% | Sell |
| Cross-check: EV/sales | n.a. | $16.88 | −64.8% | Sell |
Source: Penmark Research model, 10 Nov 2026
Five dated events test the thesis; the largest single risk to our Sell is the Neutron 50-a-year path, at +$3.83 a share
Source: Penmark Research model; Q3 FY26 call; Iridium 8-K, 20 Oct 2026
| Date | Event | Penmark | Consensus | Debate |
|---|---|---|---|---|
| Feb 2027 | Q4 FY26 results and FY27 framing | Revenue $280m; launch growth above 20% | Revenue $266.4m | 3 |
| Q1 2027 | Neutron Stage 1 tank qualification | Qualifies; first flight FY27E | Not published | 2 |
| FY27 budget cycle | Golden Dome, SDA Tranche 3 and 4 awards | Backlog adds, +$0.21 | Not published | 3 |
| 2027 | Neutron first flight | One revenue launch in FY27E | Not published | 1, 2 |
| Mid-2027 | Iridium close and EMSS renewal | 90% close; 12.5x | Not published | 4 |
Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026; Iridium 8-K, 20 Oct 2026
| Risk | Likelihood | Value per share | What it does |
|---|---|---|---|
| Against our Sell: Neutron reaches 50 launches a year | Market-implied path | +$3.83 | Value still $16.63, far below the price |
| Against our Sell: Iridium at the 16.2x deal multiple | 25% | +$2.50 | 16.2x applied to CY27E OEBITDA |
| Neutron slips again or fails on debut (Bear 1) | 40% | −$0.27 | Ramp moves a year right |
| Competitor pricing: SpaceX, Starship, new entrants (Bear 2) | 25% | −$0.37 | Neutron at $50m instead of $60m |
| Space Systems margin stalls at 32% (Bear 3) | 30% | −$0.66 | Mynaric and platform mix dilute |
| Iridium EMSS renewal at a lower rate (Bear 4) | 30% | −$1.66 | Iridium at 10.0x instead of 12.5x |
Source: Penmark Research model, 10 Nov 2026. Likelihoods are analyst judgements
Insiders sold $117m in four months with no purchases, and 18 of 22 analysts rate the stock Buy
Source: FY2025 proxy statement, 6 Apr 2026 (directors and officers, Khosla, BlackRock); Vanguard from 13F, 30 Jun 2026
Source: MarketBeat, 10 Nov 2026
Source: Form 4 filings, 8 Jul to 2 Nov 2026; no open-market purchases
Source: FINRA short interest, 30 Jun to 15 Oct 2026
| Holder | Shares | % of shares | Basis |
|---|---|---|---|
| Directors and officers | 52.4m | 8.4% | FY2025 proxy, 6 Apr 2026 |
| Khosla-affiliated entities | 34.9m | 6.1% | FY2025 proxy |
| BlackRock | 30.2m | 5.2% | FY2025 proxy |
| Vanguard | 57.4m | 9.6% of 598.4m | 13F, 30 Jun 2026 |
Source: FY2025 proxy statement (6 Apr 2026); Vanguard from 13F filings, period 30 Jun 2026
| Broker | Target change | Date |
|---|---|---|
| Piper Sandler | $83 to $58 | 10 Nov 2026 |
| Cantor Fitzgerald | $122 to $111 | 10 Nov 2026 |
| Citizens | $130 to $90 | After 14 Oct 2026 |
| KeyBanc | $135 to $100 | After 14 Oct 2026 |
| BofA | $110 to $100 | After 14 Oct 2026 |
Source: MarketBeat, 9-10 Nov 2026; Penmark Research model
Net income turns positive in FY28E at $81m and reaches $472m in FY30E; EPS passes $0.67
| Income statement and cash flow, US$m | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Revenue | 436 | 602 | 982 | 1,325 | 1,734 | 2,179 | 2,718 |
| Growth | – | 38.0% | 63.2% | 34.8% | 30.9% | 25.6% | 24.7% |
| Gross profit | 116 | 207 | 349 | 424 | 560 | 754 | 1,004 |
| EBITDA | −156 | −185 | −180 | −68 | 132 | 329 | 558 |
| EBIT | −190 | −229 | −260 | −167 | 11 | 187 | 395 |
| Net income | −190 | −198 | −196 | −41 | 81 | 257 | 472 |
| EPS ($) | −0.38 | −0.37 | −0.31 | −0.06 | 0.12 | 0.37 | 0.67 |
| Operating cash flow | −49 | −166 | −117 | 167 | 398 | 611 | 881 |
| Capex | −67 | −156 | −124 | −160 | −150 | −142 | −163 |
| Free cash flow, company definition | −116 | −322 | −241 | 7 | 248 | 469 | 718 |
| FCF excluding deposits | – | −301 | −439 | −63 | 104 | 314 | 529 |
| Ending cash and investments | 419 | 1,104 | 4,682 | 1,953 | 2,201 | 2,670 | 3,388 |
Source: Company filings (A); Penmark Research model (E). Statements are standalone; Iridium is held at cost from mid-2027. Shaded = estimates
| Margins and per-share data | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Gross margin | 26.6% | 34.4% | 35.5% | 32.0% | 32.3% | 34.6% | 36.9% |
| EBITDA margin | −35.8% | −30.7% | −18.3% | −5.1% | 7.6% | 15.1% | 20.6% |
| EBIT margin | −43.5% | −38.0% | −26.4% | −12.6% | 0.6% | 8.6% | 14.6% |
| Net margin | −43.6% | −32.9% | −19.9% | −3.1% | 4.6% | 11.8% | 17.4% |
| Weighted diluted shares (m) | 496 | 531 | 642 | 701 | 701 | 701 | 701 |
| FCF per share ($) | −0.23 | −0.61 | −0.38 | 0.01 | 0.35 | 0.67 | 1.02 |
| Dividend per share ($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/E at $54.97 | n.m. | n.m. | n.m. | n.m. | 478x | 150x | 82x |
Source: Penmark Research model. P/E at the model price of $54.97 on EPS of $0.115, $0.367 and $0.673
| Balance sheet and operating drivers | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Cash and investments, US$m | 418.9 | 1,103.7 | 4,682.3 | 1,952.9 | 2,200.6 | 2,669.7 | 3,387.8 |
| Customer deposits, US$m | 216.2 | 195.4 | 392.9 | 463.6 | 607.1 | 762.6 | 951.2 |
| Stockholders equity, US$m | 382.5 | 1,721.9 | 5,798.6 | 5,850.3 | 6,026.3 | 6,381.6 | 6,962.4 |
| Electron and HASTE launches | 16 | 21 | 25 | 30 | 33 | 36 | 38 |
| Neutron launches | 0 | 0 | 0 | 1 | 3 | 5 | 8 |
| Space Systems revenue, US$m | – | 402.8 | 743.0 | 965.9 | 1,207.3 | 1,472.9 | 1,767.5 |
| Space Systems growth | – | – | 84.4% | 30.0% | 25.0% | 22.0% | 20.0% |
Source: Company filings (A); Penmark Research model (E). Equity and cash are standalone; Iridium at cost
Revenue has risen for six straight quarters to $267.8m; gross margin has eased to 33.6% from 38.2% in Q1 FY26
| Quarterly income statement and cash flow, US$m | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 132.4 | 122.6 | 144.5 | 155.1 | 179.7 | 200.3 | 234.1 | 267.8 |
| Growth y/y | – | – | – | – | 36% | 63% | 62% | 73% |
| Launch Services | 42.4 | 35.6 | 46.6 | 40.9 | 75.9 | 63.7 | 44.6 | 53.1 |
| Space Systems | 90.0 | 87.0 | 97.9 | 114.2 | 103.8 | 136.7 | 189.5 | 214.8 |
| Gross profit | 36.8 | 35.2 | 46.4 | 57.3 | 68.2 | 76.5 | 84.6 | 90.1 |
| Gross margin | 27.8% | 28.8% | 32.1% | 37.0% | 38.0% | 38.2% | 36.1% | 33.6% |
| EBITDA | −42.4 | −50.5 | −50.9 | −47.2 | −36.3 | −41.0 | −36.6 | −57.5 |
| Net income | −52.3 | −60.6 | −66.4 | −18.3 | −52.9 | −45.0 | −49.3 | −79.7 |
| Operating cash flow | −2.4 | −54.2 | −23.2 | −23.5 | −64.5 | −50.3 | −84.1 | 7.2 |
| Free cash flow | −23.9 | −82.9 | −55.3 | −69.4 | −114.2 | −77.4 | −110.1 | −23.9 |
Source: Company 10-K and 10-Q statements and Q3 FY26 release; Q4 = full year less nine months; Penmark Research model
| Segment and KPI detail | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|
| Backlog ($m) | – | 1,067 | – | 1,100 | 1,850 | 2,200 | 2,360 | 3,570 |
| Headcount | – | – | – | 2,602 | 2,645 | – | 3,217 | 3,259 |
| Diluted shares (m) | – | 505.6 | 515.1 | 528.7 | – | 605.4 | 629.7 | 652.3 |
Source: Company releases and filings KPI; blanks are not reported
| Q4 FY26E against guidance, US$m | Guide low | Guide high | Model | Position |
|---|---|---|---|---|
| Revenue | 270 | 290 | 280.0 | Midpoint |
| GAAP gross margin | 34% | 36% | 35.0% | Midpoint |
| GAAP operating expenses | 162 | 168 | 165.0 | Midpoint |
| Adjusted EBITDA | −20 | −14 | −17.0 | Midpoint |
| Net income (model) | – | – | −22.0 | Not guided |
| EBITDA (model) | – | – | −44.5 | Not guided |
Source: Q3 FY26 release and call, 9 Nov 2026; Penmark Research model
| Quarter | Guided revenue ($m) | Actual ($m) | Versus the range |
|---|---|---|---|
| Q4 FY24 | 125 to 135 | 132.4 | Inside |
| Q1 FY25 | 117 to 123 | 122.6 | Inside |
| Q2 FY25 | 130 to 140 | 144.5 | Above |
| Q3 FY25 | 145 to 155 | 155.1 | Above |
| Q4 FY25 | 170 to 180 | 179.7 | Inside |
| Q1 FY26 | 185 to 200 | 200.3 | Above |
| Q2 FY26 | 225 to 240 | 234.1 | Inside |
| Q3 FY26 | 250 to 265 | 267.8 | Above |
Source: Company releases and Q3 FY26 call; guidance ranges as issued each quarter
Reference: Q3 FY26 adjusted EBITDA of −$18.0m is −$79.7m of reported net income
| Adjusted to reported, US$m | Q3 FY26 |
|---|---|
| Adjusted EBITDA | −18.0 |
| Less: Iridium deal costs | (21.3) |
| Less: stock-based compensation | (18.3) |
| EBITDA, operating income plus D&A | −57.5 |
| Less: depreciation and amortisation | (21.7) |
| Operating income, reported | −79.2 |
| Net interest and other income | 3.0 |
| Net income, reported (after tax $3.5m) | −79.7 |
Source: Q3 FY26 release, 9 Nov 2026; Penmark Research model
Glossary
- Electron, HASTE. Rocket Lab’s small orbital rocket and its suborbital hypersonic-test version
- Neutron. Larger reusable rocket, up to 13,000kg to low orbit; first flight no earlier than 2027
- Space Systems. Segment building satellites, solar panels, optics and components
- Backlog. Contracted revenue not yet recognised: $3.57bn at 30 Sep 2026
- ATM. At-the-market programme: shares sold gradually into the market
- 1-3-5. Management’s Neutron cadence: 1, 3 then 5 launches in successive years
Methodology note
Space Systems earns revenue from multi-year projects held in backlog; Launch earns a price per flight; Iridium would add service revenue. Value is a DCF of standalone Rocket Lab to FY40E plus Iridium at EV/OEBITDA, weighted by a 90% close probability. EV/sales is a cross-check only. P/E and EV/EBITDA are not used because earnings are negative to FY27E. Price is a 10 Nov 2026 intraday quote of $54.97; the official close was $62.71. Reporting currency is US dollars.
Data sources
- Company 10-K, 10-Q and Q3 FY26 release and call, as of 9 Nov 2026
- FY2025 proxy statement, as of 6 Apr 2026
- Form 4, 13F and FINRA short interest, as of 15 Oct to 2 Nov 2026
- Yahoo Finance prices and consensus, as of 10 Nov 2026
- MarketBeat, S&P Global via StockAnalysis, as of 6 to 10 Nov 2026
- Satellite Industry Association, US Space Force, public launch logs, as of 2025 to Nov 2026
| Measure | Definition | Source |
|---|---|---|
| Price return | 12-month target / price − 1, excluding dividends; sets the rating | Penmark rule |
| Probability-weighted value | 30% bear, 50% base, 20% bull | Model, Scenarios |
| 12-month target | Weighted value rolled 12 months at the 14.65% cost of equity | Model, Summary |
| Free cash flow, company | Operating cash flow less capex, including customer deposits | Model, Financials |
| EV/TTM sales | Enterprise value / trailing 12-month revenue to calendar Q2 2026 | Model, Peers |
Source: Penmark Research model
Analyst certification and important disclosures
Ratings
Ratings are based on the upside from the share price to our 12-month price target, excluding dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Upside to price target above +10% |
| Hold | Upside to price target from −10% to +10%, inclusive |
| Sell | Upside to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to readers of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.